他汀类药物降胆固醇作用的种族差异。
Racial Differences in the Cholesterol-Lowering Effect of Statin.
作者信息
Naito Ryo, Miyauchi Katsumi, Daida Hiroyuki
机构信息
Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine.
出版信息
J Atheroscler Thromb. 2017 Jan 1;24(1):19-25. doi: 10.5551/jat.RV16004. Epub 2016 Oct 12.
Abstract
Statin treatment to reduce low-density lipoprotein cholesterol (LDL-C) is associated with the prevention of cardiovascular events in Western patients. Similar results have been reported in studies conducted in Japan. However, the dose of statins and the degree of LDL-C reduction achieved with statins are different between Asian and Western patients. In addition, there are limited data regarding racial differences in response to statins. In this review, racial differences between Asians and Westerners in response to statins are described.
摘要
使用他汀类药物治疗以降低低密度脂蛋白胆固醇（LDL-C）与预防西方患者心血管事件相关。在日本进行的研究也报告了类似结果。然而，亚洲患者和西方患者使用他汀类药物的剂量以及他汀类药物实现的LDL-C降低程度有所不同。此外，关于他汀类药物反应的种族差异的数据有限。在本综述中，描述了亚洲人和西方人对他汀类药物反应的种族差异。
相似文献
1
Racial Differences in the Cholesterol-Lowering Effect of Statin.他汀类药物降胆固醇作用的种族差异。
J Atheroscler Thromb. 2017 Jan 1;24(1):19-25. doi: 10.5551/jat.RV16004. Epub 2016 Oct 12.
2
Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.他汀类药物的多效性作用：证据表明其益处不仅限于降低 LDL 胆固醇。
Am J Cardiovasc Drugs. 2010;10 Suppl 1:10-7. doi: 10.2165/1158822-S0-000000000-00000.
3
New therapies for reducing low-density lipoprotein cholesterol.降低低密度脂蛋白胆固醇的新疗法。
Endocrinol Metab Clin North Am. 2014 Dec;43(4):1007-33. doi: 10.1016/j.ecl.2014.08.008.
4
Statins and PCSK9 inhibitors: A new lipid-lowering therapy.他汀类药物和 PCSK9 抑制剂：一种新的降脂疗法。
Eur J Pharmacol. 2020 Jul 5;878:173114. doi: 10.1016/j.ejphar.2020.173114. Epub 2020 Apr 14.
5
The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function.他汀类药物、依折麦布、PCSK9 抑制剂、Inclisiran 和icosapent ethyl 对血小板功能的影响。
Int J Mol Sci. 2023 Jul 21;24(14):11739. doi: 10.3390/ijms241411739.
6
Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.以 PCSK9 为靶点，降低低密度脂蛋白胆固醇：一种有前途的新机制。
Pharmacol Ther. 2016 Aug;164:183-94. doi: 10.1016/j.pharmthera.2016.04.011. Epub 2016 Apr 29.
7
Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis.进一步降低起始低密度脂蛋白胆固醇水平非常低的患者的 LDL 胆固醇的疗效和安全性：一项荟萃分析。
JAMA Cardiol. 2018 Sep 1;3(9):823-828. doi: 10.1001/jamacardio.2018.2258.
8
New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.新型 LDL 胆固醇降低治疗方法：药理学、临床试验及与急性冠脉综合征的相关性。
Clin Ther. 2013 Aug;35(8):1082-98. doi: 10.1016/j.clinthera.2013.06.019. Epub 2013 Aug 8.
9
Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials.他汀类药物降低低密度脂蛋白胆固醇强度与二级卒中预防的关系：一项随机临床试验的荟萃分析。
JAMA Neurol. 2022 Apr 1;79(4):349-358. doi: 10.1001/jamaneurol.2021.5578.
10
Cardiovascular event rates and trajectories of LDL-cholesterol levels and lipid-lowering therapy in patients with atherosclerotic cardiovascular disease: A population-based cohort study.在动脉粥样硬化性心血管疾病患者中，心血管事件发生率和 LDL 胆固醇水平及降脂治疗的轨迹：一项基于人群的队列研究。
Thromb Res. 2019 Nov;183:124-130. doi: 10.1016/j.thromres.2019.09.034. Epub 2019 Oct 23.
引用本文的文献
1
Addressing global diversity in dementia research with the COSMIC collaboration.通过COSMIC合作应对痴呆症研究中的全球多样性问题。
Neuroscience. 2025 Aug 30;582:180-194. doi: 10.1016/j.neuroscience.2025.07.036. Epub 2025 Jul 24.
2
The Effect of Lipid-Lowering Therapy on Coronary Artery Plaque in East Asia Population.降脂治疗对东亚人群冠状动脉斑块的影响。
JACC Asia. 2025 Aug;5(8):1032-1047. doi: 10.1016/j.jacasi.2025.05.016. Epub 2025 Jul 15.
3
Efficacy and safety of combination therapy Ezetimibe 10/rosuvastatin 40 in Egyptian patients at very high risk of atherosclerotic cardiovascular disease.依折麦布10/瑞舒伐他汀40联合治疗对埃及动脉粥样硬化性心血管疾病极高风险患者的疗效和安全性
Egypt Heart J. 2025 Jun 11;77(1):59. doi: 10.1186/s43044-025-00655-x.
4
Bridging the United States population diversity gaps in clinical research: roadmap to precision health and reducing health disparities.弥合美国临床研究中的人口多样性差距：精准健康与减少健康差距的路线图。
Per Med. 2025 May 13:1-11. doi: 10.1080/17410541.2025.2504329.
5
Efficacy and safety of low-dose atorvastatin plus ezetimibe for primary hypercholesterolemia: A randomized, double-blind, multicenter phase 3 trial.小剂量阿托伐他汀联合依折麦布治疗原发性高胆固醇血症的疗效与安全性：一项随机、双盲、多中心3期试验。
Lipids. 2025 Sep;60(5):317-326. doi: 10.1002/lipd.12442. Epub 2025 Apr 18.
6
Exploration of metformin-based drug combination for mitigating diabetes-associated atherosclerotic diseases.探索基于二甲双胍的药物组合以减轻糖尿病相关的动脉粥样硬化疾病。
World J Diabetes. 2025 Apr 15;16(4):100533. doi: 10.4239/wjd.v16.i4.100533.
7
Epigenetic editing in cardiovascular medicine: moving beyond the hype.心血管医学中的表观遗传编辑：超越炒作
Nat Rev Cardiol. 2025 Jun;22(6):389-390. doi: 10.1038/s41569-025-01143-0.
8
Characterizing biomarkers of ageing in Singaporeans: the ABIOS observational study protocol.新加坡人衰老生物标志物的特征分析：ABIOS观察性研究方案。
Geroscience. 2025 Jan 17. doi: 10.1007/s11357-025-01511-1.
9
Risk of Sarcopenia Following Long-Term Statin Use in Community-Dwelling Middle-Aged and Older Adults in Japan.日本社区居住的中老年人长期使用他汀类药物后发生肌肉减少症的风险
J Cachexia Sarcopenia Muscle. 2025 Feb;16(1):e13660. doi: 10.1002/jcsm.13660. Epub 2024 Dec 16.
10
Moderate-Intensity Statin Plus Ezetimibe: Time to Rethink it as an Optimal Initial Lipid-Lowering Strategy.中等强度他汀类药物联合依折麦布：是时候将其重新视为一种最佳初始降脂策略了。
Drugs. 2025 Jan;85(1):51-65. doi: 10.1007/s40265-024-02113-5. Epub 2024 Nov 14.
本文引用的文献
1
The difference between Asian and Western in the effect of LDL-C lowering therapy on coronary atherosclerotic plaque: a meta-analysis report.亚洲人与西方人在低密度脂蛋白胆固醇（LDL-C）降低治疗对冠状动脉粥样硬化斑块影响方面的差异：一项荟萃分析报告
BMC Cardiovasc Disord. 2015 Feb 14;15:6. doi: 10.1186/1471-2261-15-6.
2
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.2013年美国心脏病学会/美国心脏协会成人降低动脉粥样硬化性心血管风险的血胆固醇治疗指南：美国心脏病学会/美国心脏协会实践指南工作组报告
Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45. doi: 10.1161/01.cir.0000437738.63853.7a. Epub 2013 Nov 12.
3
Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy.SLCO1B1 多态性与瑞舒伐他汀治疗后临床肌痛无关。
Am Heart J. 2013 Jun;165(6):1008-14. doi: 10.1016/j.ahj.2013.01.025. Epub 2013 Apr 10.
4
Do the lipid responses to rosuvastatin and atorvastatin differ between Chinese and Caucasians? Comparison of the DISCOVERY-Hong Kong study with other DISCOVERY studies.中国人群与高加索人群对瑞舒伐他汀和阿托伐他汀的脂质反应是否存在差异？DISCOVERY-香港研究与其他DISCOVERY研究的比较。
Int J Cardiol. 2013 Oct 3;168(3):3071-3. doi: 10.1016/j.ijcard.2013.04.091. Epub 2013 May 1.
5
Guidelines for Secondary Prevention of Myocardial Infarction (JCS 2011).心肌梗死二级预防指南（日本循环学会2011年版）
Circ J. 2013;77(1):231-48. doi: 10.1253/circj.cj-66-0053. Epub 2012 Nov 17.
6
Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.他汀类药物所致低密度脂蛋白胆固醇降低的遗传决定因素：他汀类药物在预防中的应用理由：一项评估瑞舒伐他汀的干预试验（JUPITER试验）
Circ Cardiovasc Genet. 2012 Apr 1;5(2):257-64. doi: 10.1161/CIRCGENETICS.111.961144. Epub 2012 Feb 13.
7
Comparison of the pharmacokinetics of pitavastatin by formulation and ethnic group: an open-label, single-dose, two-way crossover pharmacokinetic study in healthy Caucasian and Japanese men.制剂和种族因素对匹伐他汀药代动力学的影响比较：一项在健康白种人和日本男性中开展的开放性、单剂量、两周期交叉药代动力学研究。
Clin Drug Investig. 2011 Oct 1;31(10):735-43. doi: 10.2165/11592480-000000000-00000.
8
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).ESC/EAS 血脂异常管理指南：欧洲心脏病学会（ESC）和欧洲动脉粥样硬化学会（EAS）血脂异常管理工作组
Eur Heart J. 2011 Jul;32(14):1769-818. doi: 10.1093/eurheartj/ehr158. Epub 2011 Jun 28.
9
Race differences: modeling the pharmacodynamics of rosuvastatin in Western and Asian hypercholesterolemia patients.种族差异：在西方和亚洲高胆固醇血症患者中模拟瑞舒伐他汀的药效动力学。
Acta Pharmacol Sin. 2011 Jan;32(1):116-25. doi: 10.1038/aps.2010.169. Epub 2010 Dec 13.
10
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.更强化降低 LDL 胆固醇的疗效和安全性：来自 26 项随机试验中 170000 名参与者数据的荟萃分析。
Lancet. 2010 Nov 13;376(9753):1670-81. doi: 10.1016/S0140-6736(10)61350-5. Epub 2010 Nov 8.
Zotero 插件